Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Imaging PARP with [18F]rucaparib in pancreatic cancer models.

Journal article

Chan CY. et al, (2022), Eur J Nucl Med Mol Imaging, 49, 3668 - 3678

Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy.

Journal article

O'Neill E. and Cornelissen B., (2022), Nucl Med Biol, 108-109, 44 - 53

PARP Inhibitors in Cancer Diagnosis and Therapy.

Journal article

Chan CY. et al, (2021), Clin Cancer Res, 27, 1585 - 1594

Emerging chelators for nuclear imaging.

Journal article

CORNELISSEN B. and SNEDDON D., (2021), Current Opinion in Chemical Biology

Exploring the limits of intranuclear PET/SPECT imaging with IgG-TAT: how low can you go?

Conference paper

Veal M. et al, (2020), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47, S78 - S78

Imaging tumour CD8+T-cell infiltrates following radioimmunotherapy in an immunocompetent mouse model

Conference paper

Cornelissen B. et al, (2020), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47, S162 - S163

Ratiometric relationship between gamma H2AX imaging and Lutetium-177 is predictive of survival following radionuclide therapy in vivo

Conference paper

O'Neill E. et al, (2020), EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47, S54 - S55

Load More